Shopping Cart
- Remove All
- Your shopping cart is currently empty
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $378 | In Stock | |
5 mg | $955 | In Stock | |
10 mg | $1,530 | In Stock |
Description | Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors. |
Targets&IC50 | DR5:<1 nM |
In vitro | Activated caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells, conatumumab (0-10 μg/mL, 4 h) exhibited this effect[2]. Reducing the cell viability of sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells), conatumumab (0-10 μg/mL, 24 h) demonstrated this activity[2]. |
In vivo | In mice with Colo205, H2122, or MiaPaCa2/T2 xenograft tumors, Conatumumab (0-100 μg, intraperitoneal injection, twice a week) inhibited tumor growth[2]. Conatumumab (2.5 μg, i.p., 3 times a week) enhances the antitumor activity of chemotherapeutic drugs (CPT11) (80 mg/kg) in Colo 205 xenografts[2]. |
Alias | TRAIL-R2 mAb, AMG 655 |
Molecular Weight | 145 kDa (average) |
Cas No. | 896731-82-1 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.